C-反应蛋白白细胞介素-6和肿瘤坏死因子-α在冠心病中的变化

目的 :探讨炎症标记物与冠心病的关系及临床意义。方法 :选择健康体检者 (正常对照组 ) 30例、稳定型心绞痛 (SAP组 )患者 2 0例、不稳定型心绞痛 (UAP)患者 2 5例和急性心肌梗死 (AMI)患者 30例 ,分别测定血清中C 反应蛋白 (CRP)、白细胞介素 6 (IL 6 )和肿瘤坏死因子 α(TNF α)的浓度。结果 :①SAP、UAP、AMI与正常对照组比较 ,血清中CRP、IL 6、TNF α均显著增高 ,差异均具有统计学意义 (均P <0 .0 1) ;②UAP与SAP比较 ,血清中CRP、TNF α均显著增高 (P <0 .0 1) ,但与IL 6比较差异无统计学意义 ;③AMI与SAP比较 ,血清中CRP、IL 6、TNF α均显著增高 ,差异均具有统计学意义 (P <0 .0 1) ;④AMI与UAP比较 ,血清中CRP、IL 6、TNF α均显著增高 ,差异均具有统计学意义 (P <0 .0 5 ) ;⑤血清中CRP、IL 6、TNF α在AMI发病的 72h以内有明显动态变化。结论 :炎症参与了冠心病的发病过程 ,血清中炎症因子水平的高低与冠心病的严重程度有关 ,AMI时炎症因子的动态演变可以作为病情稳定性的指标 ,对判断病情和预后具有临床价值。     

肺炎支原体感染对老年慢性阻塞性肺疾病急性发作及肺炎患者免疫功能的影响

目的　探讨肺炎支原体感染 (MP)对老年慢性阻塞性肺疾病 (COPD)急性发作及社区获得性肺炎 (肺炎 )患者细胞免疫功能的影响。　方法　 39例老年COPD急性发作、4 0例老年肺炎患者及 30例老年健康对照者用ELISA法测定其血清MP特异性IgM、IgG抗体及干扰素 γ(IFN γ)、白细胞介素 6 (IL 6 )、肿瘤坏死因子 α(TNF α)含量 ;通过聚合酶链式反应 (PCR)法检测痰液中的MP。　结果　 (1)COPD组MPPCR法及MP IgM阳性率明显高于肺炎组及对照组 (P <0 0 5 ) ;(2 )COPD组IFN γ含量明显低于肺炎组 (P <0 0 1) ,而TNF α含量则反之 ;(3)COPD、肺炎组MP IgM阳性者IFN γ含量明显低于组内MP IgM阴性者 (P <0 0 5 )。　结论　 (1)老年人中COPD急性发作MP感染阳性率显著高于肺炎患者 ;(2 )老年COPD急性发作患者IFN γ水平明显低于老年肺炎患者 ,而TNF α、IL 6水平则显著升高 ;(3)MP感染可能抑制了老年人COPD急性发作及肺炎患者IFN γ的产生。     

肿瘤坏死因子-α和白细胞介素-6在2型糖尿病发病及骨密度改变中的作用

目的　探讨肿瘤坏死因子 α(TNF α)、白细胞介素 6 (IL 6 )在 2型糖尿病发病机制及骨密度 (BMD)改变中的作用。方法　测定 40例 2型糖尿病患者和 40例健康对照者的血清TNF α、IL 6质量浓度和左侧髋关节部位 (Fem、Troch、Ward’s三角 )及正位腰椎 (L2 L4 )BMD ,及 2型糖尿病组HbA1C、C肽、甘油三酯、HDL、BMI指标。结果　 (1)病例组TNF α、IL 6质量浓度显著高于对照组。 (2 )无论在病例组或对照组中 ,骨质疏松组的TNF α、IL 6质量浓度显著高于非骨质疏松组。 (3)病例组各部位BMD均低于对照组。 (4)病例组各部位BMD分别与TNF α、IL 6、年龄、绝经后时间呈负相关性 ,BMI只与L2 、L3 、Troch部位BMD呈负相关性。 (5 )病例组TNF α、IL 6分别与年龄、绝经后时间、BMI、甘油三酯呈正相关性 ,与HDL呈负相关性。结论　 2型糖尿病患者TNF α、IL 6质量浓度显著高于正常对照组 ,而BMD低于正常。     

培哚普利长期治疗对充血性心力衰竭患者血清细胞因子水平的影响

目的　探讨长期使用培哚普利治疗充血性心力衰竭 (CHF)患者后血清细胞因子水平变化的意义。方法　选择长期或短期使用培哚普利的缺血性与高血压性CHF患者各 32例、30例 ,正常对照组 30例 ,测定血清肿瘤坏死因子(TNF α)、白细胞介素 - 6 (IL 6 )水平并作比较。结果　CHF患者血清TNF α、IL 6水平明显高于正常对照组 (P <0 0 1) ,CHF长期使用培哚普利组TNF α、IL 6水平低于短期组 (P <0 0 5 )。结论　培哚普利可能直接或间接降低血清TNF α、IL 6水平 ,有利于改善心肌重构     

老年慢性支气管炎患者血清细胞因子检测的意义

目的　探讨白细胞介素 2 (IL 2 )、IL 6、IL 8和肿瘤坏死因子 α(TNF α)在慢性支气管炎发病机制中的作用。　 方法 　采用放射免疫法 (RIA)检测 3 0例慢性支气管炎患者急性发作期和临床缓解期血清IL 2、IL 6,IL 8及TNF α水平 ,并以 3 0例健康人血清中IL 2、IL 6、IL 8及TNF α水平作为对照。　 结果 　 3 0例慢性支气管炎患者急性发作期血清IL 6、IL 8、TNF α显著高于缓解期 (P <0 0 1) ,而缓解期血清IL 6、IL 8、TNF α与对照组相比仍然有差异 (P <0 0 1) ;IL 2浓度在发作期和缓解期均低于对照组 (P <0 0 5 ) ,但发作期和缓解期比较差异无显著性。慢性支气管炎患者急性发作期和临床缓解期血清IL 6与IL 8,IL 6与TNF α ,IL 8与TNF α水平均呈正相关 (r=0 70 9,0 63 3 ,0 615 ) ,但与IL 2水平无明显相关性。　 结论 　血清IL 2、IL 6、IL 8、TNF α不仅参与了慢性支气管炎急性感染时的发病机制 ,而且在慢性炎症的发展过程中发挥重要作用     

血清白细胞介素-6白细胞介素-8肿瘤坏死因子-α在肺癌预后判断中的意义

目的　探讨白细胞介素 6(IL 6)、白细胞介素 8(IL 8)、肿瘤坏死因子 α(TNF α)在肺癌预后判断中的意义。方法　采用ELISA方法测定 62例肺癌患者和 3 8例健康体检者血清IL 6、IL 8、TNF α的水平 ,统计学处理采用t检验作显著性分析。结果　 62例肺癌患者IL 6降低 ,而IL 8和TNF α水平升高 ,P <0 0 5。肺癌各病理类型患者血清中IL 6、IL 8、TNF α无差异 ,P >0 0 5。肺癌患者各分期存在较大差异 ,分期越晚 ,IL 6水平越低 ,而IL 8和TNF α水平越高。结论　IL 6、IL 8、TNF α是与肺癌病情变化和预后相关的细胞因子 ,可作为肺癌病情监测和预后判断的指标之一     

充血性心力衰竭患者TNF-α和IL-6变化及临床意义

目的 :探讨充血性心力衰竭患者肿瘤坏死因子 (TNF α) ,白细胞介素 6 (IL 6 )的变化及意义。方法 :56例充血性心力衰竭患者和 30例健康体检者为研究对象 ,采用酶联免疫双抗体夹心法测定血清TNF α ,IL 6浓度 ,用二维心脏超声测定左室射血分数 (LVEF)。结果 :1 血清IL 6、TNF α、去甲肾上腺素 (NE)在CHF各组均升高 ,但心功能Ⅱ级组与对照组比较差异不显著 (P >0 0 5) ;心功能Ⅲ级 ,Ⅳ级组IL 6 ,TNF α ,NE明显高于心功能Ⅱ级和对照组 (P均 <0 0 5)。IL 6、TNF α、NE与LVEF呈高度负相关(r=- 0 6 3,P <0 0 1 ;r=- 0 54,P <0 0 5;r=- 0 58,P <0 0 1 )。 2 随心衰程度加重 ,血清TNF α、IL 6和NE浓度越高。TNF α与NE ,IL 6与NE呈明显正相关 (r =0 57,P <0 0 1 ;r =0 51 ,P <0 0 5)。 3 随心衰程度加重 ,血清IL 6与TNF α浓度越高 ,且二者呈正相关 (r =0 39,P <0 0 5)。结论 :CHF患者血清TNF α和IL 6浓度升高 ,尤其中重度CHF患者更加明显 ,并与LVEF呈负相关 ,提示血清IL 6、TNF α水平可作为CHF严重程度的判断与预后指标。     

培哚普利对老年充血性心力衰竭患者血清炎性细胞因子的影响

目的 观察培哚普利对老年充血性心力衰竭(CHF)患者血清中肿瘤坏死因子(TNF—α)、白细胞介素—1(IL-1β)、白细胞介素-6(IL-6)的影响．方法 放免法检测53例老年CHF患者(培哚普利组28例，常规治疗组25例)治疗前后及25例健康老年人血清中TNF-α、IL-1β、IL—6水平．结果 老年CHF患者血清中TNF—α、IL-1β、IL—6水平显著高于对照组(P＜0．01)，且随着心功能损害程度加重而升高，TNF—α、IL—6水平在心功能各组间比较有显著性差异(P＜0．05)，IL—1β水平在心功Ⅳ级显著高于心功能Ⅱ、Ⅲ级(P＜0．05)．培哚普利组与常规治疗组老年CHF治疗后血清炎性细胞因子浓度均有明显降低，但培哚普利组TNF—α、IL-1β、IL—6水平下降更为明显(P＜0．05)。结论 血清中TNF—α、IL—1β、IL-6水平可反映心力衰竭的程度；培哚普利可明显降低老年CHF患者血清TNF—α、IL-1β、IL—6水平，从而保护和改善心脏功能．     

急性冠状动脉综合症患者血清肿瘤坏死因子-α变化的临床意义

目的探讨肿瘤坏死因子-α(TNF-α)在急性冠状动脉综合征(ACS)患者血清中浓度变化及其意义。方法选取40例ACS患者,其中不稳定型心绞痛(UAP)患者19例,急性心肌梗死(AMI)患者21例。60例非ACS患者,其中稳定型心绞痛(SAP)患者21例,陈旧性心肌梗死(OMI)患者19例。冠状动脉造影正常者20例为正常对照组,采用放射免疫法测定上述病例的血清TNF-α浓度。结果SAP、UAP、AMI、OMI患者血清TNF-α浓度均显著高于正常对照组。ACS组血清TNF-α水平显著高于非ACS组;AMI组血清TNF-α水平显著高于UAP组;SAP组与OMI组血清TNF-α水平无显著性差异;SAP与UAP患者冠状动脉狭窄程度比较无显著性差异。结论TNF-α参与冠心病的形成,并且在ACS的发病中起重要作用。检测血清TNF-α浓度将有助于诊断和预测ACS的发生、发展和预后。     

冠心病患者血清VEGF水平的研究

目的 :观测冠心病患者血清血管内皮生长因子 （VEGF）的水平。方法 :行选择性冠脉造影 （SCA）的患者 6 0例 ,分为 4组 ,其中 SCA正常者 10例作为对照组 ,急性心肌梗死 （AMI）组 2 0例 ,陈旧性心肌梗死 （OMI）组 10例 ,心绞痛 （AP）组 2 0例 ,使用 EL ISA方法分别检测其血清 VEGF的水平。结果 :AMI患者血清 VEGF水平显著高于其它各组 （P<0 .0 1） ,且其 VEGF的水平与心肌梗死部位、病变血管及血管病变程度无关 ,AP、OMI组血清 VEGF略高于对照组 ,但无统计学差异 （P>0 .0 5 ）。结论 :AMI患者血清 VEGF水平升高。     

充血性心力衰竭患者某些细胞因子的变化及胺碘酮对其影响的研究

检测充血性心力衰竭 (CHF)患者血清肿瘤坏死因子 α(TNF α)、白细胞介素 1β(IL 1β)和IL 6的变化 ,以及胺碘酮对培养的正常人及CHF患者单核细胞 (PBMC)分泌上述细胞因子的影响 ,以明确上述细胞因子在CHF发生过程中的作用 ,以及胺碘酮作用于CHF的免疫学机制。取 2 0例正常人和 2 0例Ⅲ～Ⅳ级的CHF患者静脉血 :①测其血清TNF α、IL 1β和IL 6含量 ;②离心取PBMC ,分别加入胺碘酮和脂多糖 (LPS)等 ,使胺碘酮的终浓度为 0 ,0 .1,1和10 μmol/ml进行培养 ,经 2 4h孵化后 ,取培养液上清 ,用酶联免疫吸附法 (ELISA)测培养上清中TNF α、IL 1β和IL 6。结果 :CHF患者血清TNF α、IL 1β和IL 6明显高于对照组 (P均 <0 .0 0 1) ,并随心衰程度的加重而增加 (P <0 .0 0 1)。TNF α与IL 1β和IL 6呈正相关 (r=0 .96 84,0 .9786 ;P均 <0 .0 0 1)。胺碘酮对两组PBMC分泌TNF α、IL 1β和IL 6均具有抑制作用 ,并呈剂量依赖性。结论 :①细胞因子TNF α、IL 1β和IL 6参与CHF的发生 ;②胺碘酮可能通过抑制细胞因子的产生 ,对心力衰竭患者产生改善心功能作用。     

辛伐他汀对不稳定性心绞痛患者巨噬细胞集落刺激因子及血脂水平的影响

目的　观察辛伐他汀对不稳定性心绞痛患者血清巨噬细胞集落刺激因子 (M CSF)水平的影响 ,以期探讨 3 羟 3 甲基戊二酰辅酶A还原酶抑制剂调脂以外的抗炎作用机制。方法　根据入院顺序 ,将 5 0例不稳定性心绞痛患者随机分为基本治疗组 (对照组 )与辛伐他汀 +基本治疗组 (用药组 ) ,分别于治疗前及治疗 8周后检测血脂及血清M CSF、肿瘤坏死因子 α(TNF α)及C反应蛋白 (CRP)水平。结果　用药组 8周后血清甘油三酯、低密度脂蛋白胆固醇、总胆固醇较治疗前水平下降 ,高密度脂蛋白水平轻度上升 ,而对照组无变化 ;对照组、用药组血清M CSF、TNF α、CRP水平均有降低 ,但降低的幅度用药组M CSF、TNF α明显大于对照组 ,而CRP两组间无差异。用药组治疗前后除TNF α的变化值与高密度脂蛋白变化值呈负相关外 ,M CSF、TNF α、CRP的变化与血脂各项的变化均无相关性。结论　辛伐他汀在调脂的同时 ,还通过抑制不稳定性心绞痛患者血清炎性细胞因子水平 ,发挥其抗炎作用     

Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin

The role of inflammation in acute coronary syndrome (ACS) and the mechanism by which statin treats ACS is explored. Serum high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels were measured in 50 patients with ACS [including 30 cases with unstable angina (UA) and 20 patients with acute myocardial infarction (AMI)], 34 patients with stable angina (SA), and 30 controls. Patients in the ACS group were randomly assigned to a simvastatin group (including a simvastatin AMI subgroup, n = 11 and a simvastatin UA subgroup, n = 14) and a routine group (including a routine AMI subgroup, n = 9 and a routine UA subgroup, n = 16). The simvastatin group was given simvastatin 20mg/day and the routine group a placebo. After a 3-week follow-up, serum hs-CRP, IL-6 levels, and serum lipid concentrations were measured again. Both serum IL-6 and hs-CRP levels were significantly higher in the ACS group (including the UA and AMI subgroups) than in the SA and control groups (P < 0.001). After 3 weeks of treatment with simvastatin, the serum IL-6, hs-CRP, total cholesterol, and low-density lipoprotein cholesterol levels were decreased significantly in the simvastatin group (P < 0.001), but no significant changes were observed in the routine group. No relationship was observed between the rate of decrease of serum IL-6 or hs-CRP and serum lipids levels. The hs-CRP level showed a significant correlation with IL-6 by Spearmans rank correlation analysis (P < 0.01). Inflammation plays an important role in the initiation of ACS. Simvastatin possesses an anti-inflammatory effect, independent of its lipid-lowering action, which may play an important role in the early treatment of ACS.     

Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention.

BACKGROUND: The prognostic value of interleukin (IL)-10 in patients with ST-segment elevation acute myocardial infarction (ST-se AMI) is currently unclear. The purpose of this study was to test whether the serum IL-10 level can predict 30-day mortality in patients with ST-se AMI undergoing primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: The study design was a prospective cohort study of 250 consecutive patients with ST-se AMI of onset <12 h who were undergoing primary PCI. Blood samples for serum IL-10 levels were collected in the catheterization laboratory following vascular puncture. The serum IL-10 level was also evaluated in 20 healthy and 30 at-risk control subjects. The mean serum level of IL-10 was significantly higher in the AMI patients than in either group of controls (all values of p<0.0001). Patients with a high serum IL-10 level (> or = 30 pg/ml) had a significantly lower left ventricular ejection fraction (LVEF) (defined as <50%), significantly higher incidence of cardiogenic shock, higher white blood cell (WBC) count, more advanced congestive heart failure (defined as New York Heart Association function classification of > or = 3), and increased 30-day mortality than those patients with a low serum IL-10 level (<30 pg/ml) (all values of p<0.0001). Multiple stepwise logistic regression analysis demonstrated that a high serum IL-10 level, together with low LVEF, high WBC count and unsuccessful reperfusion, was independently predictive of increased 30-day mortality (all values of p<0.005). CONCLUSION: In patients with ST-se AMI, the serum IL-10 level is a major independent predictor of 30-day mortality and should be used for early risk stratification following acute myocardial infarction.     

Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction.

OBJECTIVES: We investigated clinical implications of serum tenascin-C (TN-C) levels in patients with acute myocardial infarction (AMI). BACKGROUND: Tenascin-C, an extracellular matrix glycoprotein, is not normally expressed in the adult heart, but transiently appears during pathological conditions and plays important roles in tissue remodeling. METHODS: Serum TN-C levels were measured by ELISA in 105 AMI patients at various time points, in 10 old myocardial infarction (OMI) patients, and 20 normal controls. RESULTS: The mean serum TN-C level of AMI patients on admission (63.3 +/- 30.1 ng/ml) was significantly higher than that of controls and OMI (30.9 +/- 8.8 ng/ml and 27.4 +/- 11.7 ng/ml, respectively, p < 0.01), and peaked at 5 days (83.2 +/- 43.0 ng/ml). Follow-up examination (mean: 43.9 +/- 19.6 months) revealed that 25 of 105 AMI (23.8%) patients showed left ventricular (LV) remodeling (> or =20% end-diastolic volume increase), and in 15 (14.3%), major adverse cardiac events (MACE) were detected. The peak TN-C level was significantly higher in the remodeling group than the nonremodeling group (112 +/- 37 ng/ml vs. 66 +/- 29 ng/ml; p < 0.0001). By receiver-operating characteristic (ROC) analysis, TN-C levels clearly discriminated prediction of LV remodeling and MACE compared with other variables including plasma B-type natriuretic peptide, creatine kinase-MB, and LV function. Best predictive values of TN-C for remodeling and MACE were 84.8 and 92.8 ng/ml, respectively. Cox proportional hazards model analysis showed that TN-C was an important independent predictor of MACE. CONCLUSIONS: The findings suggest that serum TN-C levels might be useful in predicting LV remodeling and prognosis after AMI.     

早期辛伐他汀干预对不稳定型心绞痛患者血清妊娠相关蛋白A和白细胞介素-6的影响

目的探讨早期使用辛伐他汀对不稳定型心绞痛(UAP)患者血清中妊娠相关蛋白A(PAPP-A)和白细胞介素-6(IL-6)的影响。方法选择UAP患者68例,随机分为辛伐他汀组(36例);常规治疗组(32例);稳定型心绞痛(SAP)组(20例)。各组在入院时即刻检测血清中PAPP-A和IL-6水平。常规治疗组采用常规治疗(阿司匹林、依那普利、倍他乐克等),辛伐他汀组在上述治疗基础上加用辛伐他汀20mg,每晚一次,连续治疗4周。SAP组采用与辛伐他汀组同样的治疗方法。结果入院时两组UAP患者血清中PAPP-A、IL-6明显高于SAP组,两组间比较具有明显差异性(P<0.01),经治疗4周后,辛伐他汀组血清中PAPP-A、IL-6明显低于常规治疗组(P<0.01),而SAP治疗前后PAPP-A、IL-6无明显差异性。结论PAPP-A、IL-6作为炎症反应的新标志物,在UAP的发生、发展中有重要的检测意义,早期应用辛伐他汀能有效降低UAP患者血清中PAPP-A、IL-6的浓度,提高冠状动脉内粥样斑块的稳定性。     

急性心肌梗死患者PCI后白介素-6与10的变化及其意义

目的：探讨血白细胞介素-6（IL-6）及IL-10浓度在急性心肌梗死（AMI）患者急诊介入治疗后的变化及其意义。方法：选择60例行急诊经皮冠状动脉介入术（PCI）治疗患者（AMI组）和30例冠状动脉造影正常者（正常对照组）,采用酶联免疫吸附法（ELISA）检测PCI术后第1d及第7d患者的血清IL-6及IL-10的含量,并与正常对照组进行比较分析。结果：与正常对照组相比,AMI组PCI术后患者的血清IL-6[（110.34±26.01）pg/ml比（156.97±68.58）pg/ml]、IL-10[（18.21±4.0）ng/ml比（19.94±10.01）ng/ml]水平及IL-6/IL-10比值[（6.73±2.04）比（10.99±8.24）]明显升高（P〈0.05）,且IL-6与IL-10呈正相关（r=0.44,P〈0.05）;结论：急性心肌梗死后血清白细胞介素-6、白细胞介素-10水平升高,可能参与急性心肌梗死的发生和发展。     

How Does Short-Term Low-Dose Simvastatin Influence Serum Prohepcidin Levels in Patients With End-Stage Renal Disease? A Pilot Study

Anemia is a common clinical problem in end-stage renal disease (ESRD). Despite adequate erythropoiesis-stimulating agent (ESA) supplementation, some ESRD patients still have suboptimal hemoglobin levels, and iron deficiency and inflammation are recognized as the two most common causes. Hepcidin, a newly discovered key regulator of iron homeostasis, is found to be accumulated in ESRD. As it controls iron uptake and release, better reflecting real-time iron demand and availability, hepcidin might become a target in the management of iron deficiency and ESA resistance in dialysis patients. For their pleiotropic functions apart from lipid-modulation, statins are also used as anti-inflammatory or immune-modulating agents. In this study, we applied simvastatin for the purpose of influencing serum prohepcidin level in a group of maintenance hemodialysis patients. Thirty-three ESRD patients undergoing hemodialysis were enrolled and assigned to experimental and hemodialysis control groups according to their lipid profile. Nineteen healthy adults were chosen as a normal control group. The subjects in the experimental group took 20 mg simvastatin orally per night for eight weeks, and those in the hemodialysis control group took no statins or any other lipid-modulating drugs. Before and after the experiment, the serum prohepcidin concentrations, plasma IL-6, and serum C-reactive protein (CRP), ferritin, hemoglobin, albumin, total cholesterol, glycerinate, and LDL and HDL cholesterol levels were determined. Of the 33 hemodialysis patients, the serum prohepcidin concentration was (175.8 ± 52.9) ng/mL, significantly higher than that in the normal control group (149.5 ± 24.2) ng/mL (P = 0.048). In the experimental group, the serum prohepcidin level was (156.7 ± 51.9) ng/mL before treatment, and (190.6 ± 49.6) ng/mL after eight weeks (P = 0.127). In the hemodialysis control group, the serum prohepcidin level was (190.6 ± 49.6) ng/mL at the beginning, and (193.5 ± 36.0) ng/mL after eight weeks (P = 0.728). In the experimental group, after taking simvastatin for eight weeks the serum total cholesterol and triglyceride levels had lowered by 18.6% (P = 0.004) and 55.1% (P = 0.007), respectively. The plasma IL-6, serum CRP, ferritin, hemoglobin, albumin, and LDL and HDL cholesterol levels in both the hemodialysis group remained unchanged. According to our preliminary study, eight weeks of 20 mg simvastatin did not significantly change the serum prohepcidin, high-sensitive CRP, or IL-6 concentrations in the group of maintenance hemodialysis patients.     

辛伐他汀治疗急性冠脉综合征的研究

目的:探讨辛伐他汀对急性冠脉综合征(ACS)患者血清白介素-6(IL-6)及一氧化氮(NO)含量变化的影响,上述因子变化与ACS发病的关系及辛伐他汀对ACS的疗效。方法:55例ACS患者随机被分为辛伐他汀组 (n=27例)和常规治疗组(n=28例),分别于治疗前及治疗后3周行血清IL-6及NO检测。另选本院同期健康体检的30例作为对照组,对照组采血前2周内未服任何药物。结果:①ACS患者血清IL-6水平明显高于正常组,NO 水平显著低于正常组(P均<0．01);②辛伐他汀治疗后,血清IL～6水平明显降低,NO水平显著升高(P均< 0．01),但两组的IL-6、NO水平仍与正常组的有明显差别(P<0．01);③常规治疗后,血清IL-6、NO均变化不明显(P>0．05)。结论:辛伐他汀可降低急性冠脉综合征患者血IL-6水平,升高NO水平,保护血管内皮的功能。     

冠心病患者血清肿瘤坏死因子、白细胞介素-6水平及其关系

目的 :观察冠心病 （CHD）患者血清肿瘤坏死因子 （TNF）、白细胞介素 - 6 （IL- 6 ）的变化与临床意义。方法 :采用放射免疫分析法 （RIA）测定 45例 CHD患者及 30例健康者 （对照组 ）血清 TNF,IL- 6水平。结果 :CHD患者血清TNF,IL- 6水平均显著高于对照组 （P<0 .0 1） ,尤以心肌梗死患者为明显 （P<0 .0 1） ;心肌梗死组血清 TNF,IL- 6水平较心肌缺血组显著升高 （P<0 .0 1） ;急性心肌梗死患者血清 TNF,IL- 6水平高于陈旧性心肌梗死患者 （P<0 .0 5 ） ;心肌缺血组心功能 ～ 级患者血清 TNF,IL- 6水平较心功能 ～ 级患者升高显著 （P<0 .0 1） ;血清TNF水平与 IL- 6之间呈明显正相关 （r=0 .73,P<0 .0 1）。结论 :血清 TNF,IL- 6水平与 CHD病情严重程度密切相关 ,TNF,IL- 6可能参与 CHD的发生与发展。